GE HealthCare (GEHC)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-15

$69.57-1.11%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge GE HealthCare’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.1%

+10% or more+5%0%−5%−10% or less

5.44 → 5.43 EPS · FY ending Dec 31, 2027 · 13 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 12 to 13; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Free cash flow at least $1.6 billion in 2026	Cash flow remains a focus with a $1.6 billion target for 2026.	Intact	Free cash flow falls below $1.4 billion next year	Free cash flow: $-617M FY2026-Q2; GAAP. Published target: >=1.6 USD_BILLIONS. Target period is not explicitly aligned with this observation. Source published Jul 29, 2026-617,000,000 USD · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Profit margin near 16% in 2026	The company plans profit margins near 16% in 2026.	Under Pressure	Operating margin falls below 15% next year	Operating margin: 13.96% FY2026-Q2; GAAP. Published target: 15.8% to 16.1%. Target period is not explicitly aligned with this observation. Source published Jul 29, 202613.956563 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 44daf7ab-be93-4736-b513-25d81fdcc4ef. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth to about $4.9 billion per share in 2026	It targets about $4.9 billion revenue per share in 2026.	Under Pressure	Revenue growth falls below ~5.7% next year	Revenue: $5.295B FY2026-Q2; GAAP. Published target: ~4.9 USD_PER_SHARE. Target period is not explicitly aligned with this observation. Source published Jul 29, 20265,295,000,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 44daf7ab-be93-4736-b513-25d81fdcc4ef. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$5.43

$5.41 → $5.43 · observed estimates

FY2027 revenue$22.73B

$22.80B → $22.73B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$5.41	$22,800,910,704	12 / 14
2026-07-25	$5.41	$22,800,910,704	12 / 14
2026-07-26	$5.41	$22,800,910,704	12 / 14
2026-07-27	$5.41	$22,800,910,704	12 / 14
2026-07-28	$5.36	$22,778,007,470	19 / 18
2026-07-29	$5.41	$22,802,289,569	12 / 14
2026-07-30	$5.36	$22,778,007,470	19 / 18
2026-07-31	$5.41	$22,738,452,730	19 / 17
2026-08-01	$5.43	$22,740,929,697	12 / 14
2026-08-02	$5.43	$22,727,007,512	12 / 14
2026-08-03	$5.43	$22,727,007,512	12 / 14
2026-08-04	$5.40	$22,722,416,610	19 / 18
2026-08-05	$5.40	$22,722,416,610	19 / 18
2026-08-06	$5.40	$22,722,416,610	19 / 18
2026-08-07	$5.43	$22,727,007,512	12 / 14
2026-08-08	$5.43	$22,727,007,512	12 / 14
2026-08-09	$5.41	$22,721,282,190	19 / 18
2026-08-10	$5.43	$22,727,007,512	12 / 14
2026-08-12	$5.43	$22,727,007,512	12 / 14
2026-08-13	$5.43	$22,727,007,512	12 / 14
2026-08-14	$5.43	$22,727,007,512	12 / 14
2026-08-15	$5.43	$22,727,007,512	12 / 14
2026-08-16	$5.43	$22,727,007,512	12 / 14
2026-08-17	$5.43	$22,727,007,512	12 / 14
2026-08-18	$5.43	$22,727,007,512	12 / 14
2026-08-19	$5.43	$22,727,007,512	12 / 14
2026-08-20	$5.44	$22,725,820,756	12 / 14
2026-08-21	$5.44	$22,725,820,756	12 / 14
2026-08-22	$5.44	$22,725,819,126	12 / 14
2026-08-23	$5.44	$22,725,819,126	12 / 14
2026-08-24	$5.44	$22,725,819,126	12 / 14
2026-08-25	$5.44	$22,725,819,126	12 / 14
2026-08-26	$5.44	$22,726,113,244	12 / 14
2026-08-27	$5.44	$22,726,113,244	12 / 14
2026-08-28	$5.44	$22,726,113,244	12 / 14
2026-08-29	$5.44	$22,726,113,244	12 / 14
2026-08-30	$5.44	$22,726,113,244	12 / 14
2026-08-31	$5.44	$22,726,113,244	12 / 14
2026-09-01	$5.44	$22,726,113,244	12 / 14
2026-09-02	$5.44	$22,726,113,244	12 / 14
2026-09-03	$5.44	$22,726,113,244	12 / 14
2026-09-04	$5.44	$22,726,113,244	12 / 14
2026-09-05	$5.44	$22,726,096,014	12 / 14
2026-09-06	$5.44	$22,726,096,014	12 / 14
2026-09-07	$5.44	$22,726,096,014	12 / 14
2026-09-08	$5.44	$22,726,096,014	12 / 14
2026-09-09	$5.44	$22,726,096,014	12 / 14
2026-09-10	$5.44	$22,726,096,014	12 / 14
2026-09-11	$5.44	$22,726,096,014	12 / 14
2026-09-12	$5.44	$22,726,096,014	12 / 14
2026-09-13	$5.44	$22,726,096,014	12 / 14
2026-09-14	$5.44	$22,726,096,014	12 / 14
2026-09-15	$5.44	$22,726,096,014	12 / 14
2026-09-16	$5.44	$22,726,096,014	12 / 14
2026-09-17	$5.44	$22,726,096,014	12 / 14
2026-09-18	$5.44	$22,726,096,014	12 / 14
2026-09-19	$5.44	$22,726,096,014	12 / 14
2026-09-20	$5.44	$22,726,078,367	12 / 14
2026-09-21	$5.44	$22,726,078,367	12 / 14
2026-09-22	$5.44	$22,726,078,367	12 / 14
2026-09-23	$5.44	$22,726,724,014	12 / 14
2026-09-24	$5.44	$22,726,724,014	12 / 15
2026-09-25	$5.44	$22,726,724,014	12 / 15
2026-09-26	$5.44	$22,726,724,014	12 / 15
2026-09-27	$5.44	$22,726,724,014	12 / 15
2026-09-28	$5.44	$22,726,724,014	12 / 15
2026-09-29	$5.44	$22,726,724,014	12 / 15
2026-09-30	$5.44	$22,726,724,014	12 / 15
2026-10-01	$5.44	$22,726,724,014	12 / 15
2026-10-02	$5.44	$22,726,735,125	12 / 15
2026-10-03	$5.44	$22,726,735,125	12 / 15
2026-10-04	$5.44	$22,726,735,125	12 / 15
2026-10-05	$5.44	$22,726,735,125	12 / 15
2026-10-06	$5.43	$22,727,975,669	12 / 15
2026-10-07	$5.43	$22,727,975,669	12 / 15
2026-10-08	$5.43	$22,727,975,669	13 / 15
2026-10-09	$5.43	$22,727,990,286	13 / 15
2026-10-10	$5.43	$22,727,990,286	13 / 15
2026-10-11	$5.43	$22,727,990,286	13 / 15
2026-10-12	$5.43	$22,727,990,286	13 / 15
2026-10-13	$5.43	$22,726,490,286	13 / 15
2026-10-14	$5.43	$22,726,486,975	13 / 15
2026-10-15	$5.43	$22,726,486,975	13 / 15

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	14	7	1
2026-06-01	14	6	0
2026-07-01	14	6	0
2026-08-01	14	5	0
2026-09-01	15	5	0
2026-10-01	16	5	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 16 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 16–Oct 15 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 6 · prior Apr 30

$78.00 → $85.00+9.0%

NeedhamSep 22

$93.00New observation · no comparable prior

$0$51.15$102.30

1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Free cash flow at least $1.6 billion in 2026Free cash flow: $-617M
Profit margin near 16% in 2026Published status: Under Pressure
Revenue growth to about $4.9 billion per share in 2026Published status: Under Pressure

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.1%Typical daily move · historical

Downside history

-32.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

GE HealthCare outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on steady organic growth. The current thesis is intact, supported by recent strong financial performance, despite some management challenges.

What's priced into GE HealthCare

The market currently prices GEHC as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not be fully factoring in the potential for continued organic revenue growth and cash flow generation.

What the fundamentals likely do

Management is focused on achieving organic revenue growth of 3-4% for 2026, which is on track. However, the adjusted EBIT margin expansion is behind schedule, and cash flow generation shows mixed results, indicating some execution challenges.

What GE HealthCare hinges on

The long-term thesis hinges on management's ability to maintain guidance and navigate sector dynamics. Key factors include potential guidance cuts, the health of the broader job market, and performance from sector leaders that could influence GEHC's momentum.